Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Tivicay

Tivicay 5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 37–38

HOS-129199 · Präparat HOS-096689

37  observed with efavirenz is based once daily dose should be administered expected, due to induction) twice daily. In the presence of integrase class resistance alternative combinations that do not include nevirapine should be considered (see section 4.4). Rilpivirine Dolutegravir  No dose adjustment is necessary. AUC  12% Cmax  13% Cτ  22% Rilpivirine  Nucleoside Reverse Transcriptase Inhibitors Tenofovir Dolutegravir  No dose adjustment is necessary. AUC  1% Cmax  3% Cτ  8% Tenofovir  Protease Inhibitors Atazanavir Dolutegravir  No dose adjustment is necessary. AUC  91% Cmax  50% Tivicay should not be dosed higher than 30 mg Cτ  180% twice daily in combination with atazanavir (see section 5.2) due to lack of data. Atazanavir  (historical controls) (inhibition of UGT1A1 and CYP3A enzymes) Atazanavir/ritonavir Dolutegravir  No dose adjustment is necessary. AUC  62% Cmax  34% Tivicay should not be dosed higher than 30 mg Cτ  121% twice daily in combination with atazanavir (see section 5.2) due to lack of data. Atazanavir  Ritonavir  (inhibition of UGT1A1 and CYP3A enzymes) Tipranavir/ritonavir Dolutegravir  The recommended adult dose of dolutegravir (TPV+RTV) AUC  59% should be given twice daily when co-administered Cmax  47% with tipranavir/ritonavir. In paediatric patients the Cτ  76% weight-based once daily dose should be (induction of UGT1A1 and administered twice daily. CYP3A enzymes) In the presence of integrase class resistance this combination should be avoided (see section 4.4). Fosamprenavir/ Dolutegravir  No dose adjustment is necessary in the absence of ritonavir (FPV+RTV) AUC  35% integrase class resistance. Cmax  24% In the presence of integrase class resistance Cτ  49% alternative combinations that do not include (induction of UGT1A1 and fosamprenavir/ritonavir should be considered. CYP3A enzymes) Darunavir/ritonavir Dolutegravir  No dose adjustment is necessary. AUC  22% Cmax  11% C24  38% (induction of UGT1A1 and CYP3A enzymes)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) protease (HOS-085623) rilpivirine (HOS-088090) darunavir (HOS-086181) efavirenz (HOS-087947) nevirapine (HOS-088064) fosamprenavir (HOS-086182) ritonavir (HOS-084521) tipranavir (HOS-086184)